Filtered By:
Cancer: Cancer
Infectious Disease: Adenoviruses

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

UCHL1 protects against ischemic heart injury via activating HIF-1 α signal pathway
Redox Biol. 2022 Mar 18;52:102295. doi: 10.1016/j.redox.2022.102295. Online ahead of print.ABSTRACTUbiquitin carboxyl-terminal esterase L1 (UCHL1) has been thought to be a neuron specific protein and shown to play critical roles in Parkinson's Disease and stroke via de-ubiquiting and stabilizing key pathological proteins, such as α-synuclein. In the present study, we found that UCHL1 was significantly increased in both mouse and human cardiomyocytes following myocardial infarction (MI). When LDN-57444, a pharmacological inhibitor of UCHL1, was used to treat mice subjected to MI surgery, we found that administration of LDN...
Source: Cancer Control - March 27, 2022 Category: Cancer & Oncology Authors: Bingchuan Geng Xiaoliang Wang Ki Ho Park Kyung Eun Lee Jongsoo Kim Peng Chen Xinyu Zhou Tao Tan Chunlin Yang Xunchang Zou Paul M Janssen Lei Cao Lei Ye Xuejun Wang Chuanxi Cai Hua Zhu Source Type: research

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction
Breast cancer radiotherapy increases the risk of heart failure with preserved ejection fraction (HFpEF). Cardiomyocytes are highly radioresistant, but radiation specifically affects coronary microvascular endothelial cells, with subsequent microvascular inflammation and rarefaction. The effects of radiation on left ventricular (LV) diastolic function are poorly characterized. We hypothesized that cardiac radiation exposure may result in diastolic dysfunction without reduced EF. Global cardiac expression of the sodium-iodide symporter (NIS) was induced by cardiotropic gene (adeno-associated virus serotype 9) delivery to 5-w...
Source: AJP: Heart and Circulatory Physiology - August 11, 2017 Category: Cardiology Authors: Saiki, H., Moulay, G., Guenzel, A. J., Liu, W., Decklever, T. D., Classic, K. L., Pham, L., Chen, H. H., Burnett, J. C., Russell, S. J., Redfield, M. M. Tags: RESEARCH ARTICLE Source Type: research